Radspherin is under clinical development by Oncoinvent and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Radspherin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Radspherin overview
Radspherin is under development for the treatment of peritoneal metastasis originating from ovarian cancer, fallopian cancer, peritoneal cancer, colorectal cancer and unspecified cancer. It is also under development for the treatment of unspecified cancer. The drug is a alpha-radiation therapy, which contains a monoclonal antibody OI-3 conjugated to a radioisotope. The drug candidate is a suspension of inorganic alpha-emitting radioactive microspheres and administered as intraperitoneal injection. It acts by targeting CD146 antigen.
Oncoinvent overview
Oncoinvent is a pharmaceutical company that focuses on developing innovative cancer treatment options. Its main activities carry out the research and development of radiopharmaceutical drug candidates for the treatment of solid cancers. The company’s product is radspherin, a novel alpha-emitting radioactive micro particle suspension designed for local treatment of metastatic cancers in body cavities. Oncoinvent’s products are primarily aimed at providing treatment solutions for cancer patients, particularly those with peritoneal carcinomatosis originating from colorectal and ovarian cancers. It also operates a good manufacturing practice (GMP) standard production and lab facility for radiopharmaceuticals, that is capable of supplying Radspherin for large multi-center clinical studies. Oncoinvent is headquartered in Oslo, Norway.
For a complete picture of Radspherin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
